Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
53.06
-0.44 (-0.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
July 11, 2023
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a
Via
Benzinga
2 Low-Priced Stocks That Could Make You Richer
June 26, 2023
These two low-priced healthcare stocks could skyrocket within the next 12 months.
Via
The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales
May 02, 2023
Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.
Via
Investor's Business Daily
Why Incyte Shares Are Falling Today
May 02, 2023
Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the
Via
Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
May 05, 2023
The major indexes retreated for most of the week on banking fears,
Via
Investor's Business Daily
Earnings Outlook For Incyte
May 01, 2023
Via
Benzinga
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
April 21, 2023
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2. Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain...
Via
Benzinga
Ominous Death Cross Forms On Incyte's Chart
April 13, 2023
Via
Benzinga
What 13 Analyst Ratings Have To Say About Incyte
March 28, 2023
Via
Benzinga
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
March 24, 2023
The company had hoped to gain approval for an extended-release version of its biggest drug.
Via
Investor's Business Daily
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
April 14, 2023
One executive called this the most "damaging" decision in five decades.
Via
Investor's Business Daily
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday
April 10, 2023
Micron and Charles Schwab were among the top performers.
Via
Investor's Business Daily
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
April 10, 2023
Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
April 10, 2023
Via
Benzinga
Analyst Expectations for Incyte's Future
March 07, 2023
Via
Benzinga
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday
April 10, 2023
Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to...
Via
Benzinga
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
March 24, 2023
Via
Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
Why Shares of MacroGenics Climbed Thursday
March 16, 2023
The cancer-focused biotech delivered a strong earnings report.
Via
The Motley Fool
Incyte's Return On Capital Employed Overview
February 08, 2023
Via
Benzinga
Analyst Ratings for Incyte
February 08, 2023
Via
Benzinga
Earnings Outlook For Incyte
February 06, 2023
Via
Benzinga
Which S&P 500 Stocks Look Most Attractive Now?
March 08, 2023
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH.
Via
Talk Markets
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
March 06, 2023
Via
Benzinga
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
February 07, 2023
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.
Via
Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
February 07, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.